Clinical trials: SCT
Multiple Myeloma
Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma
The present study is a multicenter, prospective phase II-study to evaluate the chronic GvHD and progression-free survival at 2 years after after allogeneic stem cell transplantation for patients with multiple myeloma.
- Trial name
- NCT03700450
- Testing
- Cyclophosphamide
- Where
- 3 sites in Germany
- Volunteers
- 37 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
This is a multicenter, single-arm, phase II clinical study evaluating the efficacy and safety of neoadjuvant finotonlimab (anti-PD-1), cetuximab (anti-EGFR), and docetaxel in patients with resectable recurrent head and neck…
- Trial name
- BRIDGE (NCT07618624)
- Testing
- Finotonlimab, Cetuximab, Docetaxel
- Where
- 9 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma
Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy and safety of SCT-I10A for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma who progressed on or after platinum-based chemotherapy
- Trial name
- NCT04146181
- Testing
- PD-1
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Sinocelltech Ltd.
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
The current Standard of Care (SoC) in younger patients with Ph+ ALL is Imatinib in combination with low-dose chemotherapy, change of TKI in case of persistent MRD above 10-3 after consolidation I and indication for stem cell…
- Trial name
- GMALL-EVOLVE (NCT06061094)
- Testing
- Imatinib, Ponatinib, Blinatumomab
- Where
- 85 sites in Germany
- Volunteers
- 220 people
- Sponsor
- Goethe University
Leukemia, Lymphoma
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan) to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine), followed by an allogeneic stem cell…
- Trial name
- NCT01490723
- Testing
- Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
This is a prospective, open label, single arm, multi-centre phase II trial aiming to evaluate the safety and efficacy of Enasidenib (investigational product) as prophylactic consolidation in patients with IDH2-mutated MDS, CMML…
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation
- Trial name
- NCT04522895
- Testing
- Enasidenib
- Where
- 11 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Obsessive Compulsive Disorder (OCD)
Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder
The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of…
- Trial name
- NCT00216294
- Testing
- RG1068 (Synthetic Human Secretin)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Indiana University
Stem Cell Transplantation, Liver Diseases
Hepatic Artery Infusion of CD34+ Cells
The primary objective is to determine whether donor stem cells administered via hepatic artery infusion can produce liver cells in patients with severe hepatic dysfunction post stem cell transplantation (SCT) and the safety of…
- Trial name
- NCT00062543
- Testing
- Hepatic artery infusion of CD34+ cells, Cobe Spectra
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn what dose of a kind of immune cell called T-lymphocytes (T-cells) given as a donor infusion about 8-9 weeks after a stem cell transplant has the best results.
- Conditions
- Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
- Trial name
- NCT01518153
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
This open-label Phase I study is designed to determine the maximum tolerated dose (MTD) for CPX-351 followed by a reduced intensity conditioning regimen and incorporates a dose-escalation schedule that sequentially enrolls 6…
- Trial name
- NCT00875693
- Testing
- CPX-351
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Weill Medical College of Cornell University
Refractory Cytopenia of Childhood, Reduced Intensity Conditioning (RIC)
Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC)
This is a prospective, non-randomized multi-center multi-national study to evaluate the chimerism measured by STR and SNP in patients with hypoplastic RC and normal karyotype transplanted with a preparative regimen of reduced…
- Conditions
- Refractory Cytopenia of Childhood, Reduced Intensity Conditioning (RIC), Myelodysplastic Syndrome (MDS), Hematopoietic Stem Cell Transplantation (SCT)
- Trial name
- NCT00682799
- Where
- Germany
- Volunteers
- 112 people
- Sponsor
- Charlotte Niemeyer, MD
Acute Leukemia, Hematopoietic Stem Cell Transplantation (SCT)
Impact of Supportive Care on the Experience of Hospitalization of Patients Staying in the Protected Area of the Department of Blood Diseases
Patients with acute leukemia or received SCT are hospitalized in protected area, at least for 28 days. In this area, there is some rules like: controlled-visit, protective-clothing….so patient are in social and familial isolation…
- Conditions
- Acute Leukemia, Hematopoietic Stem Cell Transplantation (SCT), Aplasia
- Trial name
- ASTERIA (NCT03959007)
- Testing
- Aesthetic therapy sessions, Questionnaire
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Lille
Acute Myeloid Leukemia
Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML
Create a network of institutions in developing countries that will perform AML diagnosis, risk classification, treatment, supportive care and follow-up evaluation according to a common protocol and will register data using common…
- Trial name
- ICAML2015 (NCT03023384)
- Where
- 6 sites in Brazil
- Volunteers
- 547 people
- Sponsor
- International Consortium on Acute Leukemias
Graft -Versus-host-disease, aGVHD
BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation
A Phase IIb open label study evaluates the safety and efficacy of repeat doses of BPC2001 in combination with standard of care treatment for the prevention of acute graft-vs-host-disease (aGvHD) in subjects following…
- Conditions
- Graft -Versus-host-disease, aGVHD, Haploidentical Stem Cell Transplantation, cGVHD
- Trial name
- NCT07246031
- Testing
- BPC-2001
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- BioPhoenix Co., Ltd.
Head and Neck Squamous Cell Carcinoma
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy and safety of SCT-I10A plus standard chemotherapy for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma
- Trial name
- NCT04146402
- Testing
- SCT-I10A+chemo
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
This is a multi-center, phase I/II clinical trial for patients who have relapsed more than 60 day after allogeneic transplant for a hematologic malignancy. The study consists of two phases.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndromes (MDS), Lymphoma
- Trial name
- NCT01885897
- Testing
- ALT-803
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant
This study involves the use of a drug called Thymoglobulin, which is approved in the USA to treat kidney transplant rejection and in Canada to treat and to prevent kidney transplant rejection.
- Conditions
- Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
- Trial name
- NCT00088543
- Testing
- Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]
- Where
- 14 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
GVHD, AML
Haplo Peripheral Blood Sct In GVHD Prevention
This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative…
- Conditions
- GVHD, AML, ALL, MDS
- Trial name
- NCT04473911
- Testing
- FLUDARABINE, CYCLOPHOSPHAMIDE, TBI
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Zachariah Michael DeFilipp
Sickle Cell Anemia, Hemoglobinopathy
Bone Marrow Transplant From Donor Using Less Toxic Conditioning for Patient With High Risk Hemoglobinopathies
The major goal of this study is to determine the risks and benefits of stem cell transplants in combination with a newer, less toxic conditioning chemotherapy treatment in patients with severe sickle cell disease (SCD) or sickle…
- Conditions
- Sickle Cell Anemia, Hemoglobinopathy, Thalassemia
- Trial name
- NCT00040417
- Testing
- FLUDARABINE, CAMPATH-IH, Total Body Irradiation
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Leukemia, Lymphoid, Leukemia, Myeloid
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
This study is examining a chemotherapy regimen and immune suppressive medications in the setting of an allogeneic stem cell transplant.
- Conditions
- Leukemia, Lymphoid, Leukemia, Myeloid, Myelodysplastic Syndromes, Myelofibrosis
- Trial name
- FluBuATG (NCT02916979)
- Testing
- Fludarabine, Busulfan, Rabbit ATG
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center